Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sonoma Pharmaceuticals Inc
Operating Income
Sonoma Pharmaceuticals Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Operating Income
-$2.8m
|
CAGR 3-Years
24%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$26.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$16.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
23%
|
CAGR 10-Years
23%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$19.9B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
14%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$26.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
20%
|
CAGR 10-Years
12%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$29.7B
|
CAGR 3-Years
53%
|
CAGR 5-Years
34%
|
CAGR 10-Years
24%
|
|
Sonoma Pharmaceuticals Inc
Glance View
Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company is headquartered in Woodstock, Georgia and currently employs 13 full-time employees. The company went IPO on 2007-01-26. The firm's product offerings include Epicyn Antimicrobial Facial Cleanser, Levicyn Antimicrobial Dermal Spray, Levicyn Antipruritic Gel, Levicyn Antipruritic Spray Gel, Celacyn Scar Management Gel and Sebuderm Topical Gel. Its products are primarily targeted at the treatment of acne, the management of scars and atopic dermatitis. The company also has its office dispense products, such as Lasercyn Dermal Spray, Lasercyn Post Procedure Gel and Regenacyn Advanced Scar Management. The firm sells its products either directly or via partners in approximately 54 countries across the world. Its subsidiaries include Aquamed Technologies, Inc., Oculus Technologies of Mexico, S.A. de C.V. and Sonoma Pharmaceuticals Netherlands B.V.
See Also
What is Sonoma Pharmaceuticals Inc's Operating Income?
Operating Income
-2.8m
USD
Based on the financial report for Dec 31, 2025, Sonoma Pharmaceuticals Inc's Operating Income amounts to -2.8m USD.
What is Sonoma Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
14%
Over the last year, the Operating Income growth was 38%. The average annual Operating Income growth rates for Sonoma Pharmaceuticals Inc have been 24% over the past three years , 5% over the past five years , and 14% over the past ten years .
